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Abstract
Background:  The secreted enzyme autotaxin (ATX) stimulates tumor cell migration,
tumorigenesis, angiogenesis, and metastasis. ATX hydrolyzes nucleotides, but its hydrolysis of
lysophospholipids to produce lysophosphatidic acid (LPA) accounts for its biological activities. ATX
has been identified only as a constitutively active enzyme, and regulation of its activity is largely
unexplored. In spite of its presence in plasma along with abundant putative substrate LPC, the
product LPA is found in plasma at unexpectedly low concentrations. It is plausible that the LPA-
producing activity of ATX is regulated by its expression and by access to substrate(s). For this
reason studying the interaction of enzyme with substrate is paramount to understanding the
regulation of LPA production.
Results: In this study we determine ATX hydrolytic activities toward several artificial and natural
substrates. Two novel point mutations near the enzyme active site (H226Q and H434Q) confer
attenuated activity toward all substrates tested. The Vmax for LPC compounds depends upon chain
length and saturation; but this order does not differ among wild type and mutants. However the
mutant forms show disproportionately low activity toward two artificial substrates, pNpTMP and
FS-3. The mutant forms did not significantly stimulate migration responses at concentrations that
produced a maximum response for WT-ATX, but this defect could be rescued by inclusion of
exogenous LPC.
Conclusion:  H226Q-ATX and H434Q-ATX are the first point mutations of ATX/NPP2
demonstrated to differentially impair substrate hydrolysis, with hydrolysis of artificial substrates
being disproportionately lower than that of LPC. This implies that H226 and H434 are important
for substrate interaction. Assays that rely on hydrolyses of artificial substrates (FS-3 and pNpTMP),
or that rely on hydrolysis of cell-derived substrate, might fail to detect certain mutated forms of
ATX that are nonetheless capable of producing LPA in the presence of sufficient exogenous
substrate. H420Q-ATX could not be differentiated from WT-ATX, indicating that histidine at
position 420 is not required for any of the activities of ATX tested in this study.
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Background
Autotaxin (ATX, NPP2), a secreted enzyme originally puri-
fied as a tumor cell motility-stimulating factor [1],
enhances the tumorigenic and metastatic potential of
transformed cells [2], and stimulates angiogenic activity
in Matrigel™ plug assays [3], thereby affecting several fac-
ets of oncogenic progression. ATX expression has been
implicated in development [4-6], and lymphocyte traf-
ficking [7], and has been associated with a number of
pathologies including adipose tissue metabolism [8],
rheumatoid arthritis [9], Alzheimer type dementia [10],
multiple sclerosis [11], neuropathic pain [12], and a
growing list of cancer types [13].
Although products of the ATX nucleotide phosphodieste-
rase activity, such as adenosine nucleotides [14], have
been found to possess motility-stimulating activity [15],
adenosine analogs that blocked this A1-receptor-medi-
ated activity had no effect on ATX-stimulated motility
indicating that nucleotide products were not the media-
tors of ATX-stimulated migration [16].
The biological activities of ATX are now understood to
arise from its lysophospholipase D (LPLD) activity [13]
that catalyzes the conversion of lysophosphatidylcholine
(LPC) and other lysoglycerophospholipids to lysophos-
phatidic acid (LPA). A number of point mutations, each of
which abolished both the LPLD and nucleotide phos-
phodiesterase (nucleotide PDE) activities of ATX, were
found to eliminate ATX-stimulated motility. Hence, the
enzymatic active site for nucleotide PDE and LPLD coin-
cide and this intact site is required for ATX to act as a
motogen [16,17].
The LPLD, nucleotide PDE, and motility-stimulating
activities of ATX all require the presence of threonine at
(human sequence) position 210 (T210) as well as three
metal-binding histidines (H316, H360, H475) [16,17].
The catalytic domain, as well as the C-terminal and N-ter-
minal domains, are necessary for ATX's unique LPLD
activity; and a point mutation within the catalytic domain
of murine ATX (L211H equivalent to L214 in human
ATX) enhanced the nucleotide PDE activity while decreas-
ing the LPLD activity [18]. To our knowledge, this is the
only published report of a point mutation in ATX that
affects substrate preference.
We have identified two novel point mutations in the
vicinity of the active site of ATX that disproportionately
discriminate against the hydrolysis of two artificial sub-
strates (FS-3 and PpNpTMP), have attenuated activity
toward LPC, and are defective in the stimulation of migra-
tion. In this manuscript, we define the Km and Vmax of
native ATX for its various substrates, and characterize the
altered kinetic and biological properties of ATX-H226Q
and ATX-H434Q.
Results and discussion
Expression of novel mutants
Nucleotide pyrophosphatase and phosphodiesterases
(NPPs) are metallo-enzymes that contain a number of his-
tidine and aspartate residues in the presumed metal-bind-
ing site. Several of these residues have been shown to be
required for their enzymatic activities [16,17,19]. We used
site-directed mutagenesis to introduce novel histidine-to-
glutamine alterations (H226Q, H420Q, and H434Q) in
the vicinity of this NPP active site in ATX and harvested
conditioned media from transiently transfected COS-1
cells to obtain these mutant forms of ATX. Fig. 1A shows
an immunoblot of concentrated conditioned media con-
taining no ATX (NoVec), wild type (WT-ATX), H226Q-
ATX, or H434Q-ATX at normalized protein concentra-
tions.
H226Q-ATX and H434Q-ATX are substrate-selective
The enzymatic activities of the wild type vs. mutant forms
of ATX were tested for three structurally distinct types of
ATX substrates. Fig. 2 shows a comparison of hydrolytic
activities toward LPC (18:1, the putative natural substrate)
at 125 mM, toward FS-3 (an auto-quenching fluorescent
synthetic analog of LPC) at 6 mM, and toward 4 mM p-
nitrophenyl-TMP (pNpTMP, a nucleotide analog). These
substrate concentrations are approximately equal to Km
values for wild type ATX as determined in preliminary
experiments (data not shown). Initial pseudo-first order
reaction rates for WT-ATX and H420Q-ATX were indistin-
guishable for all three substrates. Compared to WT-ATX,
H226Q-ATX and H434Q-ATX showed lower but signifi-
cant hydrolytic activity toward LPC (48 and 26% of WT,
respectively). However, both H226Q-ATX and H434Q-
ATX showed parallel, but disproportionately lower, activ-
ities toward the artificial substrates, FS-3 (19 and 8% of
WT, respectively) and pNpTMP (19 and 13% of WT,
respectively). Conditioned medium containing T210A-
ATX showed no hydrolytic activity toward any of the three
substrates tested (data not shown). These data indicate
that alteration of H226 or H434 resulted in lowered activ-
ity and substrate-selectivity. H226Q and H434Q mutant
Immunoblot of autotaxin preparations Figure 1
Immunoblot of autotaxin preparations.Lipids in Health and Disease 2009, 8:4 http://www.lipidworld.com/content/8/1/4
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proteins possessed sufficient activity to hydrolyze LPC
(18:1), but could escape detection in FS-3 or pNpTMP
hydrolysis assays.
H226Q and H434Q have altered kinetic parameters
To better understand the altered hydrolytic efficiency and
substrate selectivity of H226Q-ATX and H434Q-ATX, we
determined the effects of substrate concentrations on the
reaction rates and calculated the kinetic parameters Km
and Vmax for each substrate. Fig. 3A shows the relative
hydrolytic activities of WT-, H226Q-, and H434Q-ATX
(each at 30 ng ATX protein/reaction) as a function of LPC
(18:1) concentration. Because of the low activity of
H226Q-ATX toward the substrates FS-3 and pNpTMP, we
increased the concentration of this mutant ATX to 12
times that of WT-ATX. Fig. 3B shows the relative hydro-
lytic activities of WT-ATX (30 ng ATX protein/reaction)
and H226Q-ATX (360 ng ATX protein/reaction) as func-
tions of FS-3 concentration, and Fig. 3C shows the relative
hydrolytic activities of WT-ATX and H226Q-ATX (protein/
reaction as in B) as functions of pNpTMP concentration.
Km and Vmax values from these data, normalized for ATX
protein concentration, are included in Table 1 along with
additional data described in the following section. When
H226Q-ATX is compared to WT-ATX, Vmax is lower for all
substrates tested, but these changes are disproportionately
large for FS-3 and pNpTMP compared to LPC (18:1).
These data explain the substrate selectivity noted in initial
rates of digestion. Data values for hydrolysis of FS-3 and
Substrate selectivity of H226Q and H434Q Figure 2
Substrate selectivity of H226Q and H434Q. Hydrolyses were detected as described in Methods. Reactions contained 60 
ng ATX protein and product accumulation was read beginning at 30 minutes and at intervals thereafter as indicated. A. [LPC] = 
125 μM. B. [FS-3] = 6 μM. C. [pNpTMP] = 4 mM. WT: wild type; 420: H420Q; 434: H434Q; 226: H226Q.
Kinetic analysis Figure 3
Kinetic analysis. Hydrolyses were detected as described in Methods. A. LPC hydrolysis. Reactions contained 30 ng ATX pro-
tein. B. FS-3 hydrolysis. Reactions contained 30 ng (WT) or 360 ng (H226Q) ATX protein. C. pNpTMP hydrolysis. Reactions 
contained 30 ng (WT) or 360 ng (H226Q) ATX protein. For all reactions, product formation was linear (R2 = 0.99) between 30 
minutes and 3 hours. Data are expressed as relative reaction rates [RFU (or A405)/time] and plotted against substrate concen-
trations. WT: wild type; 420: H420Q; 434: H434Q; 226: H226Q.Lipids in Health and Disease 2009, 8:4 http://www.lipidworld.com/content/8/1/4
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pNpTMP by H434Q-ATX were too low, and contained too
much scatter, to yield reliable values for kinetic parame-
ters (data not shown).
Effects of acyl chain length and saturation
We compared the kinetic parameters of the mutant forms
toward LPC 16:0, LPC 18:0, and LPC 18:1; these results
are also included in Table 1. For each species of LPC, the
mutant's activity, as assessed by determination of Vmax,
was attenuated compared to wild type; but the order of
activity profile (18:1 > 16:0 > 18:0) did not differ from
wild type, and was consonant with previous reports
[20,21].
The kinetic data demonstrate the strengths and weak-
nesses of each enzymatic assay for the detection of ATX
activity. Product formation kinetics were linear at 30 –
100 ng WT-ATX protein for FS-3 and LPC, and at 30 – 60
ng WT-ATX protein for pNpTMP (data not shown). LPC
has the advantage of being ATX-specific. Although FS-3
hydrolysis by NPP1 and NPP3 is considered unlikely
because they lack activity toward lysophospholipids,
direct evidence that FS-3 itself is resistant to hydrolysis by
NPP1 or NPP3 has not been reported and this limits the
interpretation of ATX specificity [22]. In contrast,
pNpTMP is well known to be susceptible to hydrolysis by
other NPPs. LPC has the additional advantage of being a
naturally occurring lysophospholipid whose presence can
be confirmed in a biological assay. A limitation of the LPC
enzymatic assay is that detection is coupled to choline oxi-
dase/peroxidase, which is itself susceptible to inhibition,
depending on the conditions of the assay. In addition,
Amplex® Red, the fluorescent detector for choline oxidase
activity, may be susceptible to direct hydrolysis, which we
occasionally observed in partially purified ATX prepara-
tions from transfected insect (HiFive) cell conditioned
medium (data not shown). Notably, none of the ATX
preparations used in this study (from transfected COS1
cell conditioned media) hydrolyzed Amplex® Red directly
(data not shown).
Comparison of Migration Responses
Migration responses of A2058 cells, with or without inclu-
sion of exogenous LPC (18:1), to WT-, H226Q-, and
H434Q-ATXs are shown in Fig. 4. In the absence of exog-
enous LPC, WT-ATX produced its maximal response at the
concentration of ATX used (0.23 μg/ml) (data not
shown). At the tested concentrations of LPC (0, 0.1, and
0.5 μM), the migration response to NoVec did not differ
from the background response to medium alone. WT-ATX
stimulated migration significantly above background in
the absence of exogenous LPC (p < 0.001 compared to
NoVec), suggesting that WT-ATX can generate LPA from
Table 1: Kinetic Parameters
Vmax
WT H226Q H434Q H420Q
LPC 16:0 a 306 ± 60 149 ± 63 111 ± 26 359 ± 63
LPC 18:0 a 129 ± 56 76 ± 37 NS 149 ± 49
LPC 18:1 a 589 ± 96 267 ± 59 * 107 ± 13 * 472 ± 143
FS-3 a 142 ± 4 26 ± 1 NS ND
pNpTMP b 21 ± 0.8 7 ± 2.0 NS ND
Km
WT H226Q H434Q H420Q
LPC 16:0 c 66 ± 11 126 ± 9 * 120 ± 15 * 94 ± 8
LPC 18:0 c 89 ± 9 270 ± 152 NS 115 ± 31
LPC 18:1 c 73 ± 8 126 ± 20 105 ± 21 69 ± 18
FS-3 c 2.6 ± 0.3 19 ± 1.1 NS ND
pNpTMP d 0.7 ± 0.1 4.8 ± 2.2 NS ND
a: Units are RFU/min./μg ATX protein ± SEM.
b: Units are A405 × 10000/min./μg ATX protein ± SEM.
c: Units are μM ± SEM, d: Units are mM ± SEM.
*: p < .05 vs WT (one-way ANOVA with Dunnett's post test).
NS: data not significant, ND: not determined.
Effect of LPC on migration responses Figure 4
Effect of LPC on migration responses. Values expressed 
as % WT at [LPC] = 0 (100% = 358 ± 24 nuclei/low power 
field). The total number of nuclei counted in this experiment: 
118,472. Data are shown as mean ± SEM, (DB and NoVec: 
two chambers; others: four chambers) and were compared 
by two-way ANOVA and Bonferroni's post-test (*: p <.05, 
**: p <.01, ***: p <.001, each compared to NoVec) utilizing 
Prism 4.0b (GraphPad Software, Inc, San Diego, CA). WT: 
wild type; 420: H420Q; 434: H434Q; 226: H226Q.Lipids in Health and Disease 2009, 8:4 http://www.lipidworld.com/content/8/1/4
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cell-derived substrate. Addition of exogenous LPC further
stimulated the response, suggesting that cell-derived sub-
strate can be rate limiting.
Migration stimulation by H420Q-ATX was indistinguish-
able from WT-ATX (data not shown). At tested concentra-
tions, migration stimulation by H226Q-ATX or by
H434Q-ATX, without exogenous LPC, was not signifi-
cantly different from background. Inclusion of sufficient
exogenous LPC with either mutant resulted in a signifi-
cant migration response. Together these results suggest
that, compared to WT-ATX, H226Q-ATX and H434Q-ATX
are not only less efficient in hydrolyzing exogenously-pro-
vided LPC but are also less efficient in hydrolyzing and/or
retrieving cell-derived substrate. LPC alone failed to stim-
ulate migration responses in the absence of exogenous
ATX. Therefore the migration response data reflect proper-
ties intrinsic to the various ATX constructs.
The product of extra-cellular ATX activity is LPA, a power-
ful stimulatory lipid which acts via cell surface receptors
and whose concentration must be tightly regulated in
space and time. This suggests that ATX itself is localized
near its products' site of action. If both WT-ATX and the
attenuated mutants, e.g. H226Q-ATX, have a common tar-
get, competition could occur between the two forms. To
detect a dominant negative effect of H226Q-ATX on WT-
ATX activity, we tested the migration response of WT-ATX
in the presence and absence of excessive amounts of
H226Q-ATX, and the results are shown in Fig. 5A.
At higher concentrations of H226Q-ATX (0.46 μg/ml in
Fig. 5A compared to 0.23 μg/ml in Fig. 4), there was sig-
nificant stimulation of migration in the absence of exoge-
nous LPC. At 0.46 μg/ml this activity of H226Q-ATX
contributed additively to the total activity when com-
bined with WT-ATX (Fig. 5A). We therefore did not detect
inhibition of the migration response to WT-ATX by
H226Q-ATX at 8-fold excess.
We also measured the effect of excess H226Q-ATX on the
enzymatic (LPC hydrolysis) activity of WT-ATX, and the
results are shown in Fig. 5B. Both WT-ATX and H226Q-
ATX alone showed significant enzymatic activity and, in
combination, these activities were approximately addi-
tive. We therefore did not detect inhibition of WT-ATX
LPC hydrolysis by H226Q-ATX at 4-fold excess.
The prevailing context of this study was cancer theory and
therapy, but as noted in the Background section, the find-
ings have implications for development and for other
pathologies. ATX is extra-cellular and a metallo-enzyme;
therefore it is an attractive pharmacological target. Knowl-
edge of the details of the lysophospholipase D enzyme
H226Q does not inhibit the wild type migration response or hydrolytic activity Figure 5
H226Q does not inhibit the wild type migration response or hydrolytic activity. A. Migration: Values expressed as in 
Fig. 4. [WT-ATX] = 0.06 μg/ml; [H226Q-ATX] = 0.46 μg/ml, as indicated. *: p < .001 compared to no attractant. B. LPC 
Hydrolysis: Values (mean ± SEM) expressed as % WT-ATX. [WT-ATX] = 10 ng/reaction, [H226Q-ATX] = 40 ng/reaction, 
[LPC, 18:1] = 100 μM.Lipids in Health and Disease 2009, 8:4 http://www.lipidworld.com/content/8/1/4
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mechanism can inform efforts at drug design. For exam-
ple, ATX and the other NPPs use a "ping-pong" type mech-
anism that involves two hydrolytic steps. The second step
is an attack by water on the covalent enzyme intermediate,
and this releases the final product, LPA. Enzymes using
this type of mechanism are often sensitive to product inhi-
bition, and it is now apparent that the proposed natural
inhibitor, S1P, and the recently reported synthetic inhibi-
tors, are either a product or product analog.
The role of particular amino acids within ATX in this
enzyme mechanism is incompletely understood. Studies
using chimeric constructs with regions from other NPPs
indicate that regions throughout the entire length of ATX
are irreplaceable for LPC hydrolysis. It is known that thre-
onine at position 210, the site of intermediate formation,
is absolutely required; and certain histidine residues have
been implicated as coordinators of required metals. Histi-
dine residues within enzymes can also participate directly
in other aspects of catalysis. For example, in histidine
phosphatase, histidine plays a crucial role in the phospho-
transfer reaction [23]. Measuring LPC hydrolysis and cell
migration, we screened a panel of ATX mutants lacking
particular histidine residues near to the region of histidine
residues already known to be required for activity.
Two mutants, H226Q-ATX and H434Q-ATX showed
anomalous results: they could hydrolyze LPC, albeit at a
reduced rate, but did not stimulate cell migration. The ini-
tial study, identifying plasma LPLD as ATX [24] reported
that addition of exogenous LPC stimulated the migration
response to low, but not high, concentrations of ATX. This
indicated that cell-derived substrate could be rate limiting,
and that sufficient concentrations of ATX could overcome
this limitation. Indeed in this present study, addition of
exogenous LPC supported significant migration responses
to the anomalous mutants, confirming that cell-derived
substrate was rate-limiting, and disproportionately so for
H226Q-ATX and H434Q-ATX. The discovery of these
attenuated mutants supports the conclusion that the local
production of LPA involves not only catalysis, but also
retrieval of endogenous substrate.
Conclusion
H226Q-ATX and H434Q-ATX are the first point muta-
tions of ATX/NPP2 demonstrated to differentially impair
substrate hydrolysis, including that of endogenous sub-
strate(s) in the migration assay. These two histidine resi-
dues appear to be important in ATX-substrate interaction.
H420Q-ATX could not be differentiated from WT-ATX,
indicating that histidine at position 420 is not required for
any of the activities of ATX tested in this study. There was
no apparent cross-inhibition of either migration stimula-




Except as noted, reagents were from Sigma-Aldrich (St.
Louis, MO). FS-3 was from Echelon Biosciences (Salt Lake
City, Utah), and Amplex UltraRed was from Invitrogen
Molecular Probes (Eugene, OR).
Preparation and detection of Autotaxin Proteins
The HA-tagged ATX was obtained by amplification utiliz-
ing the Platinum Pfx DNA polymerase (Invitrogen Life
Technologies, Carlsbad, CA). An antisense oligonucle-
otide primer was used to introduce the HA epitope tag




primer that we utilized to introduce a HindIII site was
(5'ATCTATCTAAGCTTATGGCAAGGAGGAGCTCGTT3').
ATX/NPP2 cDNA, derived from MDA 435 cells cloned
into pcDNA3.1 vector (pcDNA3.1wATX/NPP2) was used
as a template [2]. The PCR products were digested with
HindIII and XbaI and subsequently ligated into
pcDNA3.1 (+) to produce pcDNA3.1/HA-ATX
All point mutants of ATX were constructed utilizing the
QuikChange XL Site-Directed Mutagenesis Kit from Strat-
agene per the manufacturer's protocol (La Jolla, CA). Each
mutant plasmid was sequenced to confirm the presence of
the mutation and the fidelity of the PCR amplification.
COS-1 cells were transiently transfected with pcDNA3.1-
wtATX or with each mutant plasmid using Lipofectamine
2000 reagent (Invitrogen Life Technologies) per the man-
ufacturer's protocol. A non-vector control was produced
by adding appropriate medium and identical treatments
but no vector to COS-1 cells. Following transfection,
medium was switched to DMEM and cells were incubated
for 48 hr. The conditioned media were collected, concen-
trated, and analyzed by immunoblot using 4–12% poly-
acrylamide gels, anti-ATX-peptide rabbit polyclonal
affinity-purified primary antibody (Ab84A; 1:10,000 dilu-
tion), goat-anti-rabbit HRP-conjugated secondary anti-
body, ECL-plus (Amersham), and quantification by direct
scanning (Image Station 4000 MM, Eastman Kodak Com-
pany, Rochester, NY). Relative ATX protein concentra-
tions were determined and normalized prior to the assays
by comparing immunoblot signal intensities.
Migration Assay
Cell migration was measured using A2058 human
melanoma cells as described earlier [25] with minor mod-
ifications. These cells were maintained at 37°C in DMEM
with 10% fetal bovine serum. The chemoattractant con-
sisted of COS-1 cell conditioned media containing the
various ATX isoforms diluted in DMEM/0.1% BSA, fattyLipids in Health and Disease 2009, 8:4 http://www.lipidworld.com/content/8/1/4
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acid free (DB), with and without LPC (18:1) as indicated.
Assays were incubated under standard conditions for 3.5
hr. Migration responses were assessed by counting nuclei
that had traversed the pores and attached to the lower sur-
face of the gelatin-coated membrane (for each chamber,
six fields for each condition, at 100× magnification). Val-
ues were expressed as % of the response to WT-ATX in the
absence of endogenous LPC.
Enzyme Assays
Reaction buffer (TCB) was 50 mM Tris pH 7.4, 5 mM
CaCl2, 1 mg/ml BSA (fatty acid free); substrates and their
concentrations were included as indicated. LPC hydrolysis
assays were based on detection of released choline. The
reactions contained choline oxidase (0.1 U/ml), peroxi-
dase (1.0 U/ml), and Amplex UltraRed (10 μM). Product
formation kinetics (peroxide-driven Amplex UltraRed
hydrolysis to yield fluorescent resorufin) was monitored
by fluorimetry (Ex560 nm/Em590 nm). The assays for
hydrolysis of pNpTMP [14] and FS-3 [22] were adapted
from previously published methods. Reaction products
were detected directly by optical absorbance (A405 nm for
pNpTMP) or by fluorimetry (Ex494 nm/Em520 nm for
FS-3). Reactions (50 μl in 96 well microplates) were initi-
ated by addition of ATX (enzyme activity equivalent to 30
– 60 ng WT-ATX protein) and run at 37°C in a Tecan
Genios Plus plate reader. Automated readings were per-
formed at 15-minute intervals over a period of 2–3 hours.
Slopes were determined for the linear (steady-state) por-
tion of each reaction profile and used as reaction rates to
calculate kinetic parameters. For the conditioned media
experiments, background activity was measured using
media from mock transfections and was subtracted from
total activities to calculate ATX-specific activities. Regres-
sion analyses were calculated using Prism 4.0b (GraphPad
Software, Inc, San Diego, CA).
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TMP).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
EK performed the mutagenesis, construction of vectors,
and ATX expression. RWB developed the enzyme assay
methodology. DDR analyzed and interpreted data. TC
performed the enzyme activity and migration assays. MLS
and TC designed the study, performed statistical analysis,
and wrote the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
This research was supported by the Intramural Research Program of the 
NIH, National Cancer Institute, Center for Cancer Research.
References
1. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiff-
mann E, Liotta LA: Identification, purification, and partial
sequence analysis of autotaxin, a novel motility-stimulating
protein.  J Biol Chem 1992, 267(4):2524-2529.
2. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA, Stracke ML: Auto-
taxin (ATX), a potent tumor motogen, augments invasive
and metastatic potential of ras-transformed cells.  Oncogene
2000, 19(2):241-247.
3. Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA,
Stracke ML: Autotaxin (NPP-2), a metastasis-enhancing
motogen, is an angiogenic factor.  Cancer Res 2001,
61(18):6938-6944.
4. Ferry G, Giganti A, Coge F, Bertaux F, Thiam K, Boutin JA: Func-
tional invalidation of the autotaxin gene by a single amino
acid mutation in mouse is lethal.  FEBS Lett 2007,
581(18):3572-3578.
5. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yat-
omi Y, Aoki J, Arai H: Autotaxin stabilizes blood vessels and is
required for embryonic vasculature by producing lysophos-
phatidic acid.  J Biol Chem 2006, 281(35):25822-25830.
6. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen
MA, Pradere JP, Pettit TR, Wakelam MJ, Saulnier-Blache JS, Mummery
CL, Moolenaar WH, Jonkers J: Autotaxin, a secreted lysophos-
pholipase D, is essential for blood vessel formation during
development.  Mol Cell Biol 2006, 26(13):5015-5022.
7. Kanda H, Newton R, Klein R, Morita Y, Gunn MD, Rosen SD: Auto-
taxin, an ectoenzyme that produces lysophosphatidic acid,
promotes the entry of lymphocytes into secondary lymphoid
organs.  Nat Immunol 2008, 9(4):415-423.
8. Simon MF, Daviaud D, Pradere JP, Gres S, Guigne C, Wabitsch M,
Chun J, Valet P, Saulnier-Blache JS: Lysophosphatidic acid inhibits
adipocyte differentiation via lysophosphatidic acid 1 recep-
tor-dependent down-regulation of peroxisome proliferator-
activated receptor gamma2.  J Biol Chem 2005,
280(15):14656-14662.
9. Zhao C, Fernandes MJ, Prestwich GD, Turgeon M, Di Battista J, Clair
T, Poubelle PE, Bourgoin SG: Regulation of lysophosphatidic acid
receptor expression and function in human synoviocytes:
implications for rheumatoid arthritis?  Mol Pharmacol 2008,
73(2):587-600.
10. Umemura K, Yamashita N, Yu X, Arima K, Asada T, Makifuchi T,
Murayama S, Saito Y, Kanamaru K, Goto Y, Kohsaka S, Kanazawa I,
Kimura H: Autotaxin expression is enhanced in frontal cortex
of Alzheimer-type dementia patients.  Neurosci Lett 2006,
400(1–2):97-100.
11. Hammack BN, Fung KY, Hunsucker SW, Duncan MW, Burgoon MP,
Owens GP, Gilden DH: Proteomic analysis of multiple sclerosis
cerebrospinal fluid.  Mult Scler 2004, 10(3):245-260.
12. Inoue M, Ma L, Aoki J, Chun J, Ueda H: Autotaxin, a synthetic
enzyme of lysophosphatidic acid (LPA), mediates the induc-
tion of nerve-injured neuropathic pain.  Mol Pain 2008, 4:6.
13. van Meeteren LA, Moolenaar WH: Regulation and biological
activities of the autotaxin-LPA axis.  Prog Lipid Res 2007,
46(2):145-160.
14. Clair T, Lee HY, Liotta LA, Stracke ML: Autotaxin is an exoen-
zyme possessing 5'-nucleotide phosphodiesterase/ATP pyro-
phosphatase and ATPase activities.  J Biol Chem 1997,
272(2):996-1001.
15. Woodhouse EC, Amanatullah DF, Schetz JA, Liotta LA, Stracke ML,
Clair T: Adenosine receptor mediates motility in human
melanoma cells.  Biochem Biophys Res Commun 1998,
246(3):888-894.
16. Koh E, Clair T, Woodhouse EC, Schiffmann E, Liotta L, Stracke M:
Site-directed mutations in the tumor-associated cytokine,
autotaxin, eliminate nucleotide phosphodiesterase, lyso-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Lipids in Health and Disease 2009, 8:4 http://www.lipidworld.com/content/8/1/4
Page 8 of 8
(page number not for citation purposes)
phospholipase D, and motogenic activities.  Cancer Res 2003,
63(9):2042-2045.
17. Gijsbers R, Aoki J, Arai H, Bollen M: The hydrolysis of lysophos-
pholipids and nucleotides by autotaxin (NPP2) involves a sin-
gle catalytic site.  FEBS Lett 2003, 538(1–3):60-64.
18. Cimpean A, Stefan C, Gijsbers R, Stalmans W, Bollen M: Substrate-
specifying determinants of the nucleotide pyrophosphatases/
phosphodiesterases NPP1 and NPP2.  Biochem J 2004, 381(Pt
1):71-77.
19. Gijsbers R, Ceulemans H, Stalmans W, Bollen M: Structural and
catalytic similarities between nucleotide pyrophosphatases/
phosphodiesterases and alkaline phosphatases.  J Biol Chem
2001, 276(2):1361-1368.
20. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K,
Fukuzawa K: Identification of human plasma lysophospholi-
pase D, a lysophosphatidic acid-producing enzyme, as auto-
taxin, a multifunctional phosphodiesterase.  J Biol Chem 2002,
277(42):39436-39442.
21. Giganti A, Rodriguez M, Fould B, Moulharat N, Coge F, Chomarat P,
Galizzi JP, Valet P, Saulnier-Blache JS, Boutin JA, Ferry G: Murine and
human autotaxin alpha, beta, and gamma isoforms: gene
organization, tissue distribution, and biochemical character-
ization.  J Biol Chem 2008, 283(12):7776-7789.
22. Ferguson CG, Bigman CS, Richardson RD, van Meeteren LA, Moo-
lenaar WH, Prestwich GD: Fluorogenic phospholipid substrate
to detect lysophospholipase D/autotaxin activity.  Org Lett
2006, 8(10):2023-2026.
23. Van Etten RL: Human prostatic acid phosphatase: a histidine
phosphatase.  Ann N Y Acad Sci 1982, 390:27-51.
24. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K,
Yamori T, Mills GB, Inoue K, Aoki J, Arai H: Autotaxin has lyso-
phospholipase D activity leading to tumor cell growth and
motility by lysophosphatidic acid production.  J Cell Biol 2002,
158(2):227-233.
25. Aznavoorian S, Stracke ML, Parsons J, McClanahan J, Liotta LA:
Integrin alphavbeta3 mediates chemotactic and haptotactic
motility in human melanoma cells through different signal-
ing pathways.  J Biol Chem 1996, 271(6):3247-3254.